125 related articles for article (PubMed ID: 18441450)
21. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study.
Lunder M; Janić M; Habjan S; Sabovič M
Atherosclerosis; 2011 Apr; 215(2):446-51. PubMed ID: 21300350
[TBL] [Abstract][Full Text] [Related]
22. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity.
Yokoyama H; Kawasaki M; Ito Y; Minatoguchi S; Fujiwara H
J Am Coll Cardiol; 2005 Dec; 46(11):2031-7. PubMed ID: 16325037
[TBL] [Abstract][Full Text] [Related]
23. Long-term effects of statins on arterial pressure and stiffness of hypertensives.
Ichihara A; Hayashi M; Koura Y; Tada Y; Kaneshiro Y; Saruta T
J Hum Hypertens; 2005 Feb; 19(2):103-9. PubMed ID: 15361892
[TBL] [Abstract][Full Text] [Related]
24. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review.
Rizos EC; Agouridis AP; Elisaf MS
Curr Vasc Pharmacol; 2010 Sep; 8(5):638-44. PubMed ID: 20507272
[TBL] [Abstract][Full Text] [Related]
25. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
Herd JA
Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
[TBL] [Abstract][Full Text] [Related]
26. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
27. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
[TBL] [Abstract][Full Text] [Related]
28. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
Eliav O; Schurr D; Pfister P; Friedlander Y; Leitersdorf E
Am J Cardiol; 1995 Jul; 76(2):76A-79A. PubMed ID: 7604804
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study).
Pauciullo P; Borgnino C; Paoletti R; Mariani M; Mancini M
Atherosclerosis; 2000 Jun; 150(2):429-36. PubMed ID: 10856536
[TBL] [Abstract][Full Text] [Related]
30. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
Marian AJ; Safavi F; Ferlic L; Dunn JK; Gotto AM; Ballantyne CM
J Am Coll Cardiol; 2000 Jan; 35(1):89-95. PubMed ID: 10636265
[TBL] [Abstract][Full Text] [Related]
31. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.
Boncelj Svetek M; Eržen B; Kanc K; Šabovič M
J Diabetes Complications; 2017 Mar; 31(3):544-550. PubMed ID: 28012835
[TBL] [Abstract][Full Text] [Related]
32. Fluvastatin: a review of its use in lipid disorders.
Langtry HD; Markham A
Drugs; 1999 Apr; 57(4):583-606. PubMed ID: 10235694
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
Knopp RH; Frohlich J; Jokubaitis LA; Dawson K; Broyles FE; Gomez-Coronado D
Am J Med; 1994 Jun; 96(6A):69S-78S. PubMed ID: 8017470
[TBL] [Abstract][Full Text] [Related]
34. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
Eichstädt HW; Eskötter H; Hoffman I; Amthauer HW; Weidinger G
Am J Cardiol; 1995 Jul; 76(2):122A-125A. PubMed ID: 7604786
[TBL] [Abstract][Full Text] [Related]
35. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
Inoue T; Hayashi M; Takayanagi K; Morooka S
Atherosclerosis; 2002 Feb; 160(2):369-76. PubMed ID: 11849660
[TBL] [Abstract][Full Text] [Related]
36. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
Muratti EN; Peters TK; Leitersdorf E
Am J Cardiol; 1994 May; 73(14):30D-38D. PubMed ID: 8198022
[TBL] [Abstract][Full Text] [Related]
37. [Effect of fluvastatin extended release on the protein-lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia].
Broncel M; Balcerak M; Cieślak D; Duchnowicz P; Koter-Michalak M; Sikora J; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Feb; 22(128):107-11. PubMed ID: 17598653
[TBL] [Abstract][Full Text] [Related]
38. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
39. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound.
Nasu K; Tsuchikane E; Katoh O; Tanaka N; Kimura M; Ehara M; Kinoshita Y; Matsubara T; Matsuo H; Asakura K; Asakura Y; Terashima M; Takayama T; Honye J; Hirayama A; Saito S; Suzuki T
JACC Cardiovasc Interv; 2009 Jul; 2(7):689-96. PubMed ID: 19628194
[TBL] [Abstract][Full Text] [Related]
40. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
